Nitric oxide-releasing non-steroidal anti-inflammatory drugs: a new generation of antithrombotics?

Bibliography

• PATRONO C: Aspirin as an antiplatelet drug. New Engl.
   Google Scholar
• •J. Med. (1994) 330:1287-1294. Excellent review of the pros and cons of aspirin as an antithrombotic drug.
   Google Scholar
• STEERING COMMITTEE OF THE PHYSICIANS' HEALTH STUDY RESEARCH GROUP: Final report on the aspirin component of the ongoing Physicians' Health Study. New Engl. J. Med. (1989) 321:129–135.
   PubMed Web of Science ®Google Scholar
• THE RISC GROUP: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet (1990) 336:827–830.
   PubMed Web of Science ®Google Scholar
• THE SALT COLLABORATIVE GROUP: Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular is chaemic events. Lancet (1991) 338:1345–1349.
   PubMed Web of Science ®Google Scholar
• FITZGERALD GA: Mechanisms of platelet activation: thromboxane Ay as an amplifying signal for other agonists. Am. J. Cardiol. (1991) 68:11B–15B.
   Google Scholar
• PATRONO C, CIABATTONI G, PINCA E et al.: Low dose aspirin and inhibition of thromboxane By production in healthy subjects. Thromb. Res. (1980) 17:317–327.
   PubMed Web of Science ®Google Scholar
• LEE M, CRYER B, FELDMAN M: Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann. Intern. Med. (1994) 120:184–189.
   PubMed Web of Science ®Google Scholar
• WARE JA, HEISTAD DD: Platelet-endothelium interac-tions. New Engl. J. Med. (1993) 328:628–635.
   PubMed Web of Science ®Google Scholar
• RADOMSKI MW, PALMER RMJ, MONCADA S: The anti-ag-gregating properties of vascular endothelium: interac-tions between prostacyclin and nitric oxide. Br. J. Pharmacol. (1987) 92:639–646.
   PubMed Web of Science ®Google Scholar
• RADOMSKI MW, PALMER RMJ, MONCADA S: Comparative pharmacology of endothelium-derived relaxing factor,nitric oxide and prostacyclin in platelets. Br. j Pharma-col. (1987) 92:181-187. Comprehensive evaluation of the effects of NO and prostacyclin as inhibitors of platelet aggregation.
   Google Scholar
• SEGASOTHY M, SAMAD SA, ZULFIGAR A, BENNETT WM: Chronic renal disease and papillary necrosis associated with the long-term use of non-steroidal anti-inflamma-tory drugs as the sole or predominant analgesic Am. J. Kidney as. (1994) 24:17–24.
   PubMed Web of Science ®Google Scholar
• MEADE TW, RODERICK PJ, BRENNAN PJ, VILKES HC, KELLEHER CC: Extracranial bleeding and other symp-toms due to low dose aspirin and low intensity oral anticoagulation. Thromb. Haemost. (1992) 68:1–6.
   PubMed Web of Science ®Google Scholar
• CRYER B, LUK G, FELDMAN M: Effects of very low doses of aspirin (ASA) on gastric, duodenal 8E rectal pro-staglandins (PGs) and mucosal injury. Gastroenterology (1995) 108:A77.
   Web of Science ®Google Scholar
• KURATA JH, ABBEY DE: The effect of chronic aspirin use on duodenal and gastric ulcer hospitalisation. J. Clin. Gastroenterol. (1990) 12:260–266.
   PubMed Web of Science ®Google Scholar
• OATES JA, FITZGERALD GA, BRANCH RA et al: Clinical implications of prostaglandin and thromboxane Az formation. /V. ew Engl. J. Med. (1988) 319:761–767.
   PubMed Web of Science ®Google Scholar
• PATRONO C, DUNN MJ: The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int. (1987) 32:1–12.
   PubMed Web of Science ®Google Scholar
• HALL D, ZEITLER H, RUDOLPH W: Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J. Am. Coll. Cardiol. (1992) 20:1549–1555.
   PubMed Web of Science ®Google Scholar
• VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature NewBiol. (1971) 231:232-235. First demonstration that aspirin-like drugs inhibit prostaglaidin synthesis. One of the major findings that led to the award of the Nobel Prize for Medicine/Physiology to Dr Vane in 1982.
   Google Scholar
• WALLACE JL: Non-steroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gas-troenterology (1997). A review of the pathogenesis of NSAID-induced gastroenteropathy and strategies being employed to develop GI-sparing NSAIDs.
   Google Scholar
• WALLACE JL, GRANGER DN: The cellular and molecular basis for gastroduodenal mucosal defense. FASEB (1996) 10:731–740.
   PubMed Web of Science ®Google Scholar
• WHITTLE BJR: Neuronal and endothelium-derived mediators in the modulation of the gastric microcircula-tion: integrity in the balance. Br. J. PharmacoL (1993) 110:3-17. Excellent review of the influence of various endothelium-derived mediators in modulating gastrointestinal mucosal integrity, with a focus on the effects of these mediators on the gastric microcircula-tion.
   Google Scholar
• BROWN JF, HANSON PJ, WHITTLE BJR: Nitric oxide do- nors increase mucus gel thickness in rat stomach. Eur. Pharmacol (1992) 223:101–104.
   Web of Science ®Google Scholar
• ELLIOTT SN, MCKNIGHT W, CIRINO G, WALLACE JL: Anitric oxide-releasing non-steroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroen-terology (1995) 109:524–530.
   PubMed Web of Science ®Google Scholar
• WALLACE JL, REUTER B, CICALA C eta].: Novel non-steroi-dal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterol-ogy (1994) 107:173-179. First demonstration that NO-releasing NSAIDs had markedly reduced gastrointestinal toxicity, but were as effective as the parent NSAID in terms of anti-inflammatory activity.
   Google Scholar
• WALLACE JL, REUTER B, CICALA C et al.: A diclofenacderivative without ulcerogenic properties. Eur. J. Phar-macol (1994) 257:249–255.
   PubMed Web of Science ®Google Scholar
• REUTER BK CIRINO G, WALLACE JL: Markedly reduced intestinal toxicity of a diclofenac derivative. Life Sci. (1994) 55:PL1-PL8. This paper demonstrated that NO-releasing NSAIDs had markedly reduced damaging effects on the small intestine, and did not exacerbate pre-existing colitis, as standard NSAIDs did.
   Google Scholar
• DAVIES NM, ROSETH AG, APPLEYARD CB et al: NO- naproxen versus naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol 7her. (1997) 11:69–79.
   Google Scholar
• FUJIHARA CK, MALHEIROS DMAC, ANTUNES E et al.: Nitroflurbiprofen, a novel non-steroidal anti-inflam-matory drug, limits glomerular injury in the remnant model [Abstract]. J. Am. Soc. Neph. (1995) 6:1012.
   Web of Science ®Google Scholar
• CIRINO G, CICALA C, MANCUSO F, BAYDOUN AR, WAL-LACE JL: Flurbinitroxybutylester: a novel anti-inflam-matory drug has erhanced antithrombotic activity. Thromb. Res. (1995) 79:73–81.
   PubMed Web of Science ®Google Scholar
• WALLACE JL, MCKNIGHT W, DEL SOLDATO P, BAYDOUN
   Google Scholar
• ••AR, CIRINO G: Antithrombotic effects of a nitric oxide-releasing gastric-sparing aspirin derivative. J. Clin. In-vest. (1995) 96:2711-2718. Characterisation of the antiplatelet effects of NCX-4215 and demon-stration that the drug produces these effects through generation of NO.
   Google Scholar